The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through four segments: Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure and BaiMax brands for delivering whiteness, brightness, opacity, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging. The Thermal & Specialized Solutions segment offers of refrigerants, thermal management solutions, propellants, foam blowing agents, and specialty solvents. The Advanced Performance Materials segment products portfolio includes various industrial resins, specialty products, membranes, and coatings for consumer electronics, semiconductors, digital communications, transportation, energy, oil and gas, and medical, and others applications. The Chemical Solutions segment comprises a portfolio of industrial chemicals used as raw materials and catalysts for gold production, clean and disinfect, oil and gas, water treatment, electronics, and automotive applications. The company sells its products through direct and indirect channels, as well as through a network of resellers and distributors. The Chemours Company was founded in 2014 and is headquartered in Wilmington, Delaware.
Chemours Stock Performance
Shares of CC opened at $34.49 on Monday. The company has a market cap of $5.35 billion, a PE ratio of 6.43, a price-to-earnings-growth ratio of 0.43 and a beta of 1.82. The company has a current ratio of 1.91, a quick ratio of 1.27 and a debt-to-equity ratio of 3.01. The stock has a 50-day moving average price of $34.93 and a 200-day moving average price of $33.69. Chemours has a 12-month low of $22.56 and a 12-month high of $44.95.
Chemours (NYSE:CC - Get Rating) last announced its quarterly earnings data on Thursday, July 28th. The specialty chemicals company reported $1.89 earnings per share for the quarter, beating analysts' consensus estimates of $1.42 by $0.47. The company had revenue of $1.92 billion for the quarter, compared to analysts' expectations of $1.84 billion. Chemours had a return on equity of 79.77% and a net margin of 12.72%. Chemours's revenue for the quarter was up 15.7% compared to the same quarter last year. During the same period last year, the firm posted $1.20 EPS. As a group, equities analysts forecast that Chemours will post 5.53 earnings per share for the current fiscal year.
Chemours Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 15th. Investors of record on Monday, August 15th will be issued a dividend of $0.25 per share. The ex-dividend date is Friday, August 12th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 2.90%. Chemours's dividend payout ratio is 18.66%.
Analyst Ratings Changes
Several research analysts have commented on the company. Citigroup raised their target price on Chemours from $32.00 to $36.00 in a research note on Wednesday, August 3rd. Barclays raised their target price on Chemours from $37.00 to $46.00 in a research note on Monday, May 9th. Bank of America downgraded Chemours from a "buy" rating to a "neutral" rating and cut their target price for the stock from $48.00 to $44.00 in a research note on Tuesday, June 14th. Royal Bank of Canada raised their target price on Chemours from $44.00 to $48.00 and gave the stock an "outperform" rating in a research note on Monday, August 1st. Finally, UBS Group raised their target price on Chemours from $35.00 to $37.00 and gave the stock a "neutral" rating in a research note on Friday, July 29th. Three analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $40.17.
Insider Activity at Chemours
In related news, insider Edwin C. Sparks sold 22,142 shares of the firm's stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $43.59, for a total transaction of $965,169.78. Following the transaction, the insider now directly owns 101,038 shares of the company's stock, valued at approximately $4,404,246.42. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 3.04% of the stock is currently owned by insiders.